51-08-1

Basic information

• Product Name: 4-amino-N-(2-piperidinoethyl)benzenecarboxamide
• Synonyms: 4-amino-N-(2-piperidinoethyl)benzenecarboxamide
• CAS NO: 51-08-1
• Molecular Formula: C₁₄H₂₁N₃O
• Molecular Weight: 247.34
• Mol File: 51-08-1.mol

Chemical Properties

• Melting Point: 118-120°
• Appearance: /
• CAS DataBase Reference: 4-amino-N-(2-piperidinoethyl)benzenecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-N-(2-piperidinoethyl)benzenecarboxamide(51-08-1)
• EPA Substance Registry System: 4-amino-N-(2-piperidinoethyl)benzenecarboxamide(51-08-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 51-08-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-amino-N-(2-piperidinoethyl)benzenecarboxamide is used as an antiarrhythmic medication for the treatment of ventricular arrhythmias, a condition characterized by irregular heartbeats. Its application is based on its mechanism of action, which involves the blocking of sodium channels in the heart muscle, thereby stabilizing the heart rhythm and preventing the occurrence of life-threatening arrhythmias.
The use of procainamide in the pharmaceutical industry is also supported by its versatility in administration, being available for both oral and intravenous routes, allowing for flexible treatment options depending on the patient's condition and needs.
Furthermore, the monitoring of procainamide blood levels is crucial in ensuring the appropriate dosage and minimizing the risk of toxic effects, which is an important aspect of its application in clinical settings. Common side effects associated with its use include nausea, dizziness, and low blood pressure, which are managed through careful dosage adjustment and patient monitoring.

Upstream product

• 1664-31-9 4-nitro-N-(2-(piperidin-1-yl)ethyl)benzamide 
• 66493-39-8 4-(N-tert-butoxycarbonyl)aminobenzoic acid 
• 27578-60-5 1-(2-aminoethyl)piperidine 
• 122-04-3 4-nitro-benzoyl chloride 
• 2038-03-1 4-(2-AMINOETHYL)MORPHOLINE 

Downstream Products

• 1197166-08-7 4-{[(4-{4-morpholin-4-yl-6-[(3S)-tetrahydrofuran-3-yloxy]-1,3,5-triazin-2-yl}phenyl)carbamoyl]amino}-N-(2-piperidin-1-ylethyl)benzamide 
• 1197162-90-5 4-({[4-(4-methoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-(2-piperidin-1-ylethyl)benzamide 

Relevant articles and documents

Comparative study of dG affinity vs. DNA methylation modulating properties of side chain derivatives of procainamide: Insight into its DNA hypomethylating effect

Procainamide derivatives have been synthesized to investigate the role of side chains in modulating the DNA methylation level in cancer cells and gain insight into its mechanism of action. The synthesized derivatives comprised of flexible (dimethyl), cons

A platinum(ii) phenylphenanthroimidazole with an extended side-chain exhibits slow dissociation from a c-kit G-quadruplex motif

A series of three platinum(II) phenanthroimidazoles each containing a protonable side-chain appended from the phenyl moiety through copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) were evaluated for their capacities to bind to human telomere, c-Myc, and c-Kit derived G-quadruplexes. The side-chain has been optimized to enable a multivalent binding mode to G-quadruplex motifs, which would potentially result in selective targeting. Molecular modeling, high-throughput fluorescence intercalator displacement (HT-FID) assays, and surface plasmon resonance (SPR) studies demonstrate that complex 2 exhibits significantly slower dissociation rates compared to platinum phenanthroimidazoles without side-chains and other reported G-quadruplex binders. Complex 2 showed little cytotoxicity in HeLa and A172 cancer cell lines, consistent with the fact that it does not follow a telomere-targeting pathway. Preliminary mRNA analysis shows that 2 specifically interacts with the ckit promoter region. Overall, this study validates 2 as a useful molecular probe for c-Kit related cancer pathways. Bound to impress: A series of three platinum(II) phenanthroimidazoles each containing a protonable side-chain appended from the phenyl moiety through copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC), was evaluated for their capacity to bind to human telomere, c-Myc, and c-Kit derived G-quadruplexes (see scheme). The presence of the side-chain enables a multivalent binding mode to G-quadruplex motifs. Copyright

Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors

The o-carboxylic acid substituted bisanilinopyrimidine 1 was identified as a potent hit (Aurora A IC50 = 6.1 ± 1.0 nM) from in-house screening. Detailed structure-activity relationship (SAR) studies indicated that polar substituents at the para position of the B-ring are critical for potent activity. X-ray crystallography studies revealed that compound 1 is a type I inhibitor that binds the Aurora kinase active site in a DFG-in conformation. Structure-activity guided replacement of the A-ring carboxylic acid with halogens and incorporation of fluorine at the pyrimidine 5-position led to highly potent inhibitors of Aurora A that bind in a DFG-out conformation. B-Ring modifications were undertaken to improve the solubility and cell permeability. Compounds such as 9m with water-solubilizing moieties at the para position of the B-ring inhibited the autophosphorylation of Aurora A in MDA-MB-468 breast cancer cells.

Design, synthesis, and biological evaluation of novel water-soluble N-mustards as potential anticancer agents

A series of novel water-soluble N-mustard-benzene conjugates bearing a urea linker were synthesized. The benzene moiety contains various hydrophilic side chains are linked to the meta- or para-position of the urea linker via a carboxamide or an ether link

NOVEL CARBOXAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS

Novel compounds of formula (I) which modulate MCH activity are disclosed, in which A is a linker; B is a connecting moiety; Ar1 and Ar2 are aryl or heteroaryl groups; R1 and R2 are hydrogen, halogen atoms, CF3, OCF3/